FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281777556> ?p ?o ?g. }

• W4281777556 endingPage "e21154" @default.
• W4281777556 startingPage "e21154" @default.
• W4281777556 abstract "e21154 Background: Osimertinib (osi) is the preferred 1 st line (1L) therapy for patients (pts) with EGFR-mutant NSCLC, but acquired resistance is universal. Identification of mechanisms of resistance (MoR) to 1L osi can inform subsequent treatment strategies. Here, we report MoRs identified at our institution from tissue and/or liquid biopsy (bx) upon 1L osi progression. Methods: We included pts seen at MGH with advanced EGFR+ NSCLC who had tissue and/or liquid bx (for ctDNA analysis) obtained at progression on 1L osi. Molecular testing was performed using local next-generation sequencing (NGS) and, when available, MET/ EGFR FISH. We retrospectively collected clinical characteristics, tissue histology and NGS results. Results: 54 pts (38 Female; median age 61 yrs) had tissue (n = 35) and/or liquid (n = 32) bx upon progression on 1L osi between November 2016-January 2022. 13/54 pts had both tissue and ctDNA testing. Primary EGFR mutations included del19 (32), L858R (16) and other (6). Median time from osi start to 1st resistance bx was 12.3 mos (range, 1-37). MoRs are summarized in the table. Among 35 pts with tissue bx, histologic transformations (trans) were the most common MoR, seen in 23% pts, including both small cell histology (tSCLC; 5/35), squamous histology (tSqCC; 2/35) and 1 pt with both SCLC + SqCC features in one bx. Among 5 pts with tSCLC and pre-trans NGS, only 2 had baseline TP53/RB1 loss. MET amp was seen in 20% tissue (including one with tSqCC) and secondary EGFR mutations in 9%; 43% of tissue bx had no identified MoR. Among 32 pts with ctDNA NGS, secondary EGFR mutations (16%) were the most prevalent MoR, with MET amp seen in 13%. 65% pts had no MoR by ctDNA. 6/13 pts with both tissue and ctDNA had concordant findings (MET amp-2, EGFR L718Q – 1; No MoR - 3). As expected, the 2 pts with tSCLC had no MoR in ctDNA. In 2 cases, MET amp was seen in tissue but not ctDNA; the converse was true in 1 pt. Conclusions: Histologic transformations were the most common MoR to first-line osimertinib accounting for 23% tissue biopsies and, in 3/5 pts, occurred in the absence of the known risk factor of baseline TP53/RB1 loss. In this small cohort, MET amp was more commonly seen in tissue than in ctDNA, and 63% of liquid biopsies showed no detectable MoR. Our findings suggest that tissue biopsy is critical for complete evaluation of MoRs in pts progressing on first line osimertinib, and that tissue and ctDNA may be complementary.[Table: see text]" @default.
• W4281777556 created "2022-06-13" @default.
• W4281777556 creator A5013091949 @default.
• W4281777556 creator A5025951912 @default.
• W4281777556 creator A5027545163 @default.
• W4281777556 creator A5029774909 @default.
• W4281777556 creator A5039324896 @default.
• W4281777556 creator A5065614369 @default.
• W4281777556 creator A5069070706 @default.
• W4281777556 creator A5075333926 @default.
• W4281777556 creator A5087906702 @default.
• W4281777556 date "2022-06-01" @default.
• W4281777556 modified "2023-09-29" @default.
• W4281777556 title "Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy." @default.
• W4281777556 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e21154" @default.
• W4281777556 hasPublicationYear "2022" @default.
• W4281777556 type Work @default.
• W4281777556 citedByCount "0" @default.
• W4281777556 crossrefType "journal-article" @default.
• W4281777556 hasAuthorship W4281777556A5013091949 @default.
• W4281777556 hasAuthorship W4281777556A5025951912 @default.
• W4281777556 hasAuthorship W4281777556A5027545163 @default.
• W4281777556 hasAuthorship W4281777556A5029774909 @default.
• W4281777556 hasAuthorship W4281777556A5039324896 @default.
• W4281777556 hasAuthorship W4281777556A5065614369 @default.
• W4281777556 hasAuthorship W4281777556A5069070706 @default.
• W4281777556 hasAuthorship W4281777556A5075333926 @default.
• W4281777556 hasAuthorship W4281777556A5087906702 @default.
• W4281777556 hasConcept C121608353 @default.
• W4281777556 hasConcept C126322002 @default.
• W4281777556 hasConcept C142724271 @default.
• W4281777556 hasConcept C143998085 @default.
• W4281777556 hasConcept C2775934546 @default.
• W4281777556 hasConcept C2775999482 @default.
• W4281777556 hasConcept C2777626846 @default.
• W4281777556 hasConcept C2781182431 @default.
• W4281777556 hasConcept C57742111 @default.
• W4281777556 hasConcept C71924100 @default.
• W4281777556 hasConceptScore W4281777556C121608353 @default.
• W4281777556 hasConceptScore W4281777556C126322002 @default.
• W4281777556 hasConceptScore W4281777556C142724271 @default.
• W4281777556 hasConceptScore W4281777556C143998085 @default.
• W4281777556 hasConceptScore W4281777556C2775934546 @default.
• W4281777556 hasConceptScore W4281777556C2775999482 @default.
• W4281777556 hasConceptScore W4281777556C2777626846 @default.
• W4281777556 hasConceptScore W4281777556C2781182431 @default.
• W4281777556 hasConceptScore W4281777556C57742111 @default.
• W4281777556 hasConceptScore W4281777556C71924100 @default.
• W4281777556 hasIssue "16_suppl" @default.
• W4281777556 hasLocation W42817775561 @default.
• W4281777556 hasOpenAccess W4281777556 @default.
• W4281777556 hasPrimaryLocation W42817775561 @default.
• W4281777556 hasRelatedWork W1953375745 @default.
• W4281777556 hasRelatedWork W2039641526 @default.
• W4281777556 hasRelatedWork W2153471799 @default.
• W4281777556 hasRelatedWork W2318521325 @default.
• W4281777556 hasRelatedWork W2339326149 @default.
• W4281777556 hasRelatedWork W2801190576 @default.
• W4281777556 hasRelatedWork W2985223206 @default.
• W4281777556 hasRelatedWork W3197306284 @default.
• W4281777556 hasRelatedWork W4295168981 @default.
• W4281777556 hasRelatedWork W56819729 @default.
• W4281777556 hasVolume "40" @default.
• W4281777556 isParatext "false" @default.
• W4281777556 isRetracted "false" @default.
• W4281777556 workType "article" @default.